Barinthus Bio Completes Phase 1 Celiac Disease Trial as Company Prepares for Strategic Merger
核心洞察
Barinthus Bio (搜索) successfully completed the single ascending dose portion of its Phase 1 AVALON trial for VTP-1000 in celiac disease (搜索), enrolling 18 patients across three placebo-controlled cohorts with no treatment-related serious adverse events.
The company reported encouraging pharmacodynamic results showing T cell (搜索) recognition of VTP-1000 across all patient cohorts, with multiple ascending dose data expected in the second half of 2026.
Barinthus Bio (搜索) is proceeding with its planned merger with Clywedog Therapeutics (搜索), expected to close in Q2 2026, creating a combined company focused on metabolic and autoimmune diseases with cash runway extending through 2027.
Barinthus Bio (搜索) announced the successful completion of the single ascending dose portion of its Phase 1 AVALON trial for VTP-1000, a novel immunotherapy candidate for celiac disease (搜索), while advancing toward a strategic merger that will reshape the company's focus on autoimmune and metabolic disorders.
Phase 1 Trial Results Show Promise
The AVALON trial (NCT06310291) enrolled 18 patients across three placebo-controlled cohorts of ascending doses in December 2025. VTP-1000 demonstrated a favorable safety profile, with the treatment being well tolerated at all dose levels and no treatment-related serious adverse events reported.
Pharmacodynamic analyses provided encouraging evidence of biological activity, with IL-2 response measurements confirming T cell (搜索) recognition of VTP-1000 in celiac patients across all cohorts. This immune recognition represents a critical mechanism for the SNAP-Tolerance Immunotherapy (SNAP-TI) platform underlying VTP-1000's therapeutic approach.
"We finished 2025 reporting encouraging results from the single ascending dose portion of the Phase 1 AVALON clinical trial of VTP-1000 in celiac disease (搜索), and expect multiple ascending dose data in the second half of 2026," said Bill Enright, Chief Executive Officer of Barinthus Bio (搜索). "These upcoming results will help us confirm whether VTP-1000 has the potential to be disease-modifying by restoring balance to the immune system."
Strategic Merger to Create Combined Entity
Barinthus Bio (搜索) is proceeding with its planned all-stock merger with Clywedog Therapeutics (搜索), a private company developing breakthrough medicines in diabetes (搜索). The transaction, expected to complete in the second quarter of 2026, will create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets.
Upon closing, the combined entity will be renamed "Clywedog Therapeutics (搜索) Holdings, Inc." and trade on NASDAQ under the ticker symbol "CLYD." The merger received additional flexibility in February 2026 through an amendment to the definitive agreement that updated the exchange ratio framework and revised certain minimum cash requirements to reflect anticipated transaction timing.
The combined company's estimated cash runway is expected to extend through 2027, supported by existing cash and additional investments from OrbiMed and TPAV, LLC, both existing Clywedog shareholders, along with new investors. The merged entity anticipates four clinical data milestones within 18 months of closing.
Financial Position and Strategic Refocus
As of December 31, 2025, Barinthus Bio (搜索) reported cash, cash equivalents and restricted cash of $71.9 million, compared to $112.4 million the previous year. The $40.5 million decrease primarily resulted from $48.0 million in operating activities, including pipeline development and general corporate expenses.
Research and development expenses decreased to $25.6 million in 2025 from $42.2 million in 2024, reflecting the company's strategic refocus announced in January 2025. The restructuring prioritized immunology and inflammation indications while deprioritizing infectious disease and oncology assets, collectively referred to as "Barinthus legacy assets."
VTP-1000 development expenses totaled $6.1 million in 2025, representing the primary focus of the company's autoimmune program. Legacy asset expenses, including VTP-300 for chronic hepatitis B (搜索) and VTP-850 for prostate cancer (搜索), are expected to continue decreasing as clinical trials complete.
Upcoming Clinical Milestones
The multiple ascending dose portion of the Phase 1 AVALON trial is currently progressing and includes a gluten challenge following three doses of test medication. Data from this critical phase is expected in the second half of 2026, which will provide insights into VTP-1000's potential disease-modifying effects in celiac disease (搜索) patients.
The company expects its available resources to fund operating expenses and capital expenditure requirements for at least the next 12 months based on standalone research and development plans. Following the merger completion, the combined entity will advance a differentiated portfolio targeting both metabolic and autoimmune diseases.